McKesson Corporation $MCK Shares Acquired by Carnegie Investment Counsel

Key Points

• Carnegie Investment Counsel increased its McKesson position by 56.1% in the third quarter, bringing its holdings to 4,242 shares valued at approximately $3.62 million. Institutional investors collectively own 85.07% of the company.
• McKesson reported quarterly earnings of $9.93 per share, beating estimates of $9.56, while revenue rose 7.7% year over year to $105.38 billion. The company maintained fiscal 2027 EPS guidance of $44.20–$45.00.
• Analysts remain broadly positive, with 15 Buy ratings and four Holds producing a “Moderate Buy” consensus and an average price target of $997.12. McKesson also declared a quarterly dividend of $0.94 per share, representing an annualized yield of about 0.4%.

Carnegie Investment Counsel raised its position in McKesson Corporation (NYSE:MCK - Free Report) by 56.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,242 shares of the company's stock after acquiring an additional 1,525 shares during the quarter. Carnegie Investment Counsel's holdings in McKesson were worth $3,622,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Secure Asset Management LLC raised its holdings in shares of McKesson by 484.8% during the second quarter. Secure Asset Management LLC now owns 2,123 shares of the company's stock valued at $1,604,000 after acquiring an additional 1,760 shares in the last quarter. Royal London Asset Management Ltd. lifted its stake in McKesson by 1.1% in the second quarter. Royal London Asset Management Ltd. now owns 112,241 shares of the company's stock worth $84,809,000 after acquiring an additional 1,216 shares during the period. Benchmark Investment Advisors LLC purchased a new stake in McKesson in the second quarter worth $441,000. Summit Global Investments purchased a new stake in McKesson in the second quarter worth $1,159,000. Finally, One Wealth Advisors LLC bought a new stake in McKesson in the second quarter valued at $1,494,000. 85.07% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Bradley E. Lerman sold 301 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $892.33, for a total transaction of $268,591.33. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Napoleon B. Rutledge, Jr. sold 111 shares of McKesson stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $891.45, for a total value of $98,950.95. Following the transaction, the chief accounting officer owned 521 shares of the company's stock, valued at $464,445.45. The trade was a 17.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,212 shares of company stock worth $1,164,182 in the last 90 days. Insiders own 0.06% of the company's stock.

Analyst Ratings Changes

MCK has been the topic of a number of research analyst reports. Mizuho boosted their price objective on shares of McKesson from $905.00 to $1,020.00 and gave the company a "neutral" rating in a research report on Tuesday. Royal Bank Of Canada restated a "sector perform" rating and issued a $845.00 price objective on shares of McKesson in a report on Monday, September 14th. Morgan Stanley set a $977.00 target price on shares of McKesson in a research report on Tuesday, October 6th. Wells Fargo & Company raised their target price on shares of McKesson from $812.00 to $933.00 and gave the stock an "equal weight" rating in a research report on Tuesday, August 11th. Finally, Leerink Partners lifted their target price on shares of McKesson from $1,030.00 to $1,070.00 and gave the company an "outperform" rating in a research note on Wednesday, October 7th. Fifteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $997.12.

Key Headlines Impacting McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Analyst price-target increases supported the long-term outlook. UBS raised its target to $1,200, while Mizuho lifted its target to $1,020 from $905, although Mizuho maintained a neutral rating. The analyst actions followed McKesson’s recent strength and helped the stock reach a new one-year high. UBS raises target for McKesson
• Positive Sentiment: McKesson declared its regular quarterly dividend. The company will pay $0.94 per share on January 4, 2027, to shareholders of record on December 1. The dividend provides continuity for income-focused investors, though the annualized yield is modest at approximately 0.4%. McKesson declares quarterly dividend
• Neutral Sentiment: Investor attention remains elevated. McKesson was among the more-trending stocks on Zacks, but the article primarily reviews existing fundamentals rather than introducing a new catalyst. Its latest reported quarter showed earnings and revenue above estimates, with revenue up 7.7% year over year and fiscal 2027 EPS guidance of $44.20–$45.00. Is Trending Stock McKesson a Buy Now?
• Negative Sentiment: An executive sale may have added modest selling pressure. EVP Francisco Fraga sold 800 shares worth approximately $796,640. However, the transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, reducing its significance as a discretionary bearish signal. McKesson executive stock sale

McKesson Price Performance

Shares of NYSE MCK opened at $1,014.79 on Thursday. McKesson Corporation has a 1 year low of $723.68 and a 1 year high of $1,030.27. The firm has a 50-day moving average of $905.65 and a 200 day moving average of $840.38. The stock has a market cap of $118.31 billion, a P/E ratio of 25.24, a price-to-earnings-growth ratio of 2.05 and a beta of 0.30.

McKesson (NYSE:MCK - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $9.93 earnings per share for the quarter, topping analysts' consensus estimates of $9.56 by $0.37. McKesson had a net margin of 1.12% and a negative return on equity of 253.21%. The business had revenue of $105.38 billion for the quarter, compared to analysts' expectations of $103.88 billion. During the same quarter in the prior year, the company earned $8.26 earnings per share. The business's revenue was up 7.7% compared to the same quarter last year. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. Research analysts expect that McKesson Corporation will post 44.71 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, January 4th. Stockholders of record on Tuesday, December 1st will be given a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Tuesday, December 1st. McKesson's payout ratio is currently 10.06%.

McKesson Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and medical products to pharmacies, hospitals, health systems, physicians and other healthcare providers. The company also provides technology, data and business solutions designed to support prescription management, pharmacy operations and patient care.

McKesson's principal activities include pharmaceutical distribution, medical-surgical supply distribution, specialty pharmaceutical services and oncology care support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.